{"nctId":"NCT00673231","briefTitle":"Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin","startDateStruct":{"date":"2008-04"},"conditions":["Type 2 Diabetes"],"count":1240,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Dapagliflozin"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: Dapagliflozin"]},{"label":"3","type":"EXPERIMENTAL","interventionNames":["Drug: Dapagliflozin"]},{"label":"4","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Dapagliflozin","otherNames":[]},{"name":"Dapagliflozin","otherNames":[]},{"name":"Dapagliflozin","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Dapagliflozin","otherNames":[]},{"name":"Dapagliflozin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 Diabetes\n* Patients with HbA1c ≥7.5% and ≤10.5% and who are on a stable insulin regimen of at least 30 IU of injectable insulin per day either without any other oral antidiabetic drug or with a stable dose of oral antidiabetic drugs\n\nExclusion Criteria:\n\n* Type 1 Diabetes\n* Treatment with more than two additional oral antidiabetic drugs\n* Moderate and severe renal (kidney) failure or dysfunction","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Adjusted Mean Change in HbA1c Levels","description":"To assess the efficacy of 2.5 mg, 5 mg and 10 mg dapagliflozin compared to placebo as add-on therapy to insulin in improving glycaemic control in participants with type 2 diabetes who have inadequate glycaemic control on ≥ 30 IU injectable insulin daily for at least 8 weeks prior to enrolment, as determined by the change in HbA1c levels from baseline to Week 24, excluding data after insulin up-titration.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.30","spread":null},{"groupId":"OG001","value":"-0.75","spread":null},{"groupId":"OG002","value":"-0.82","spread":null},{"groupId":"OG003","value":"-0.90","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change in Body Weight","description":"To examine whether treatment with dapagliflozin in combination with insulin is superior in reducing body weight or causing less weight gain as compared to placebo added to insulin treatment after 24 weeks of treatment (LOCF), excluding data after insulin up-titration.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":null},{"groupId":"OG001","value":"-0.98","spread":null},{"groupId":"OG002","value":"-0.98","spread":null},{"groupId":"OG003","value":"-1.67","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change in Calculated Mean Daily Insulin Dose","description":"To examine whether treatment with dapagliflozin in combination with insulin leads to a lower absolute calculated mean daily insulin dose as compared to placebo added to insulin treatment alone, from baseline to week 24, including data after insulin up-titration.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.08","spread":null},{"groupId":"OG001","value":"-1.80","spread":null},{"groupId":"OG002","value":"-0.61","spread":null},{"groupId":"OG003","value":"-1.16","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants With Calculated Mean Daily Insulin Dose Reduction","description":"To examine whether treatment with dapagliflozin in combination with insulin leads to higher percentage of participants with calculated mean daily insulin dose reduction from baseline to week 24 (i.e. reduction \\>= 10%) as compared to placebo added to insulin treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.0","spread":null},{"groupId":"OG001","value":"18.1","spread":null},{"groupId":"OG002","value":"16.8","spread":null},{"groupId":"OG003","value":"19.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change in Fasting Plasma Glucose (FPG)","description":"To examine whether treatment with dapagliflozin in combination with insulin is superior in reducing Fasting Plasma Glucose (FPG) as compared to placebo added to insulin treatment after 24 weeks of treatment, excluding data after insulin up-titration.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":null},{"groupId":"OG001","value":"-12.5","spread":null},{"groupId":"OG002","value":"-18.8","spread":null},{"groupId":"OG003","value":"-21.7","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Proportion of Participants With Lack of Glycemic Control","description":"Participants with lack of glycemic control or insulin up-titration for failing to achieve pre-specified glycemic targets","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"24","spread":null},{"groupId":"OG003","value":"19","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":197},"commonTop":["Hypoglycemia","Nasopharyngitis","Hypertension","Urinary Tract Infection","Headache"]}}}